OD
ODI Pharma AB
ODI.ST · STO
2.22 kr -2.63% (-0.06 kr)
1M -15.91%
Market Cap 41.4M kr
P/E Ratio -
Div. Yield -
ROE 22.93%
Bulios Fair Price
2.59 kr
16.7% upside
Current Price
2.22 kr
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ODI.ST is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
21 /100
Expensive P/B 23.15x
EV/EBITDA 50.17x
P/S 1.40x
Growth
78 /100
Growing Book val. growth 55.54%
Rev. growth 115.01%
FCF growth N/A
Profitability
6 /100
Weak Op. margin 2.15%
Gross margin 14.06%
FCF margin 17.74%
Quality
55 /100
Average ROA 2.63%
ROIC 36.16%
Asset turnover 2.81x
Debt
75 /100
Low Int. coverage 1.06x
Debt/Equity 0.00x
Net debt/EBITDA -5.64x
Stability
26 /100
Unstable EPS volatility 467.33%
Beta 0.79x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ODI.ST
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jan-Mark Edewaard
Employees
1
Headquarters
Stockholm